20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19+0.00 (+1.30%)
Close on Nov 17, 2026Market cap $2.39MP/E –Yield –
20/20 Biolabs revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was $2.05M, up 16.7% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.05M | +16.7% |
| FY2024 | Dec 31, 2024 | $1.75M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $730.57K | – |
| Q1 FY2026 | Mar 31, 2026 | $353.38K | – |
| Q2 FY2025 | Jun 30, 2025 | $535.06K | – |
| Q1 FY2025 | Mar 31, 2025 | $553.82K | – |
See a number that looks wrong?